U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07120776) titled 'Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial' on Aug. 01.
Brief Summary: Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction). Often individuals with HOCM suffer from chest pain and shortness of breath due to lack of oxygen supply (ischaemia) to the heart muscle in the absence of blockages in the coronary arteries.
Despite proven advances in treatment of LVOT obstruction with the novel medication Camzyos (Mavacamten)...